ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2008
Population-based laboratory surveillance for Serratia species isolates in a large Canadian health region.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Serratia Bacteraemia in the North Denmark Region: A Population-Based Study (2010-2024).APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Characterization and complete genomic sequence of a novel phage BUCT805 infectingMicrobiology spectrum · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Clinical and Microbiological Profile ofInfection and drug resistance · 2026Article
- Impact of Multifaceted Interventions Including Waterless Patient Care on Endemic Occurrence ofPathogens (Basel, Switzerland) · 2025Article
- RecurrentTranslational pediatrics · 2024Article
- Article
- Outbreak ofAdvances in medicine · 2023Article
- Susceptibility Tests and Predictions of Transporter Profile inMicroorganisms · 2022Article
- Bacterial Keratitis:Current eye research · 2022Article
- The Role of Gram-Negative Bacteria in Urinary Tract Infections: Current Concepts and Therapeutic Options.Advances in experimental medicine and biology · 2021Review
- Effects of Selected Functional Bacteria on Maize Growth and Nutrient Use Efficiency.Microorganisms · 2020Article
- Draft Genome Sequence of a Serratia marcescens Strain Isolated from the Pitcher Fluids of aMicrobiology resource announcements · 2020Article
- Serratia Liver Abscess Infection and Cardiomyopathy in a Patient with Diabetes Mellitus: A Case Report and Review of the Literature.The American journal of case reports · 2019Review
- Resistance Trends and Epidemiology ofMedicina (Kaunas, Lithuania) · 2019Article
- The Evolution of Breast Implant Infections:Plastic surgery (Oakville, Ont.) · 2019Article
- Recent independent emergence of multiple multidrug-resistant Serratia marcescens clones within the United Kingdom and Ireland.Genome research · 2016Article
- Risk factors for mortality in patients with Serratia marcescens bacteremia.Yonsei medical journal · 2015Article
- Requirement for Serratia marcescens cytolysin in a murine model of hemorrhagic pneumonia.Infection and immunity · 2015Article
- Pink Breast Milk: Serratia marcescens Colonization.AJP reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A population-based laboratory surveillance was conducted during a six-year period to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of Serratia species isolates. A total of 715 incident Serratia species isolates were identified for an annual incidence of 10.8 per 100,000 residents; bacteremic disease occurred in 0.9 per 100,000 residents annually. The incidence increased with advancing age and males were at the highest risk. Ninety-two percent of the isolates were Serratia marcescens, and the majority (65%) of incident Serratia species isolates were of community onset. Ninety-five percent of isolates were susceptible to ciprofloxacin, 98% to gentamicin, 98% to trimethoprim/sulfamethoxazole, and >99% to imipenem. No yearly increase in resistance was observed. Serratia species isolation is most commonly of community onset and older patients and males are at increased risk. Despite reports of increasing resistance among Serratia species, the incidence in our region remains at a low stable rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.